Retreatment of patients who do not respond to initial therapy for chronic hepatitis C

Cleveland Clinic Journal of Medicine

Volumn 71, Issue SUPPL. 3, 2004, Pages

  Shiftman, Mitchell L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN; VIRUS RNA; AMANTADINE; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; DRUG DERIVATIVE; IMMUNOLOGICAL ADJUVANT; INTERFERON; THYMOSIN; THYMOSIN ALPHA1;

DRUG RESPONSE; GENOTYPE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LONG TERM CARE; MAINTENANCE THERAPY; MONOTHERAPY; RETREATMENT; REVIEW; TREATMENT OUTCOME; VIRUS LOAD; AFRICAN AMERICAN; ALCOHOLISM; BLOOD; CAUCASIAN; CLINICAL TRIAL; COUNSELING; DRUG COMBINATION; GENETICS; HEPATITIS C VIRUS; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; PATIENT COMPLIANCE; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; AFRICAN AMERICANS; ALCOHOLISM; AMANTADINE; ANTIVIRAL AGENTS; CLINICAL TRIALS; COUNSELING; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERONS; LIVER CIRRHOSIS; META-ANALYSIS; OLIGONUCLEOTIDES, ANTISENSE; PATIENT COMPLIANCE; RIBAVIRIN; RNA, VIRAL; THYMOSIN; TIME FACTORS;

EID: 6044275663     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment, Gastroenterology. In press.
2. Heathcote EJ, Keeffe EB, Lee SS, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27:1136-1143.
3. Younossi ZM, Perrillo RP. The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAlDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Semin Liver Dis 1999; 19(suppl 1):95-102.
4. 1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology 1998; 27:1128-1135.
5. Gordon SC, Bacon BR, Jacobson IM, et al. Treatment of chronic hepatitis C with ISIS 14803, an antisense inhibitor of HCV, given for 12 weeks. Hepatology 2003; 38(suppl 1):306A. Abstract.
6. Shiffman ML, Hofmann CM, Gabbay J, et al. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. Am J Gastroenterol 2000; 95:2928-2935.
7. Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology 2002; 36(5 suppl 1):S220-S225.
8. Nichols M, Kugelmas M. Reasons for discontinuation of treatment of chronic hepatitis C. An interim analysis of the Frontier Trial. Gastroenterology 2003; 124(suppl 1):A703. Abstract.
9. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
10. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652.
11. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98:2491-2499.
12. Afdhal NH, Dieterich DT, Pockros PJ, et al. Correction of anemia with epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind study. Gastroenterology. In press.
13. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23:1334-1340.
14. McHutchison JG, Gordon S, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-1492.
15. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:1426-1432.
16. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
17. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
18. Shiffman ML, Hofmann CM, Contas MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117:1164-1172.